Osiris Therapeutics (OSIR) 15.95 $OSIR
Osiris Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results Conference Call
Business Wire - Wed Feb 11, 7:02AM CST
Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will report its financial results for fourth quarter and full year ended December 31, 2014, on Thursday, March 5, 2015. Lode Debrabandere, Ph.D., President and Chief Executive Officer, and Philip R. Jacoby, Jr., Chief Financial Officer, will provide a company update and discuss results via a webcast and conference call on Thursday, March 5, 2015, at 9:00 a.m. ET.
OSIR: 15.95 (+0.28)
Osiris Therapeutics Shares Up 18.6% Since SmarTrend's Buy Recommendation (OSIR)
Comtex SmarTrend(R) - Mon Feb 02, 9:24AM CST
SmarTrend identified an Uptrend for Osiris Therapeutics (NASDAQ:OSIR) on October 28th, 2014 at $13.68. In approximately 3 months, Osiris Therapeutics has returned 18.64% as of today's recent price of $16.23.
OSIR: 15.95 (+0.28)
Uptrend Call Working As Osiris Therapeutics Stock Rises 23.9% (OSIR)
Comtex SmarTrend(R) - Fri Jan 23, 4:47PM CST
SmarTrend identified an Uptrend for Osiris Therapeutics (NASDAQ:OSIR) on October 28th, 2014 at $13.68. In approximately 3 months, Osiris Therapeutics has returned 23.90% as of today's recent price of $16.95.
OSIR: 15.95 (+0.28)
Osiris Therapeutics Shares Up 21.2% Since SmarTrend's Buy Recommendation (OSIR)
Comtex SmarTrend(R) - Fri Jan 16, 11:12AM CST
SmarTrend identified an Uptrend for Osiris Therapeutics (NASDAQ:OSIR) on October 28th, 2014 at $13.68. In approximately 3 months, Osiris Therapeutics has returned 21.20% as of today's recent price of $16.58.
OSIR: 15.95 (+0.28)
TiGenix: A Deeply Undervalued Stem Cell Company With Upcoming Catalysts
Logribel Biostocks - Seeking Alpha - Tue Jan 13, 8:59AM CST
TiGenix ( OTC:TGXSF ) -- listed on Euronext Brussels -- is a leading but little known Belgian cell therapy biotech with an advanced adipose-derived allogeneic stem cell product platform in various clinical stages. TiGenix also has a commercialized...
PFE: 34.64 (-0.23), OSIR: 15.95 (+0.28), GSK: 47.94 (+1.99), ATHX: 2.12 (unch)
Osiris Therapeutics Up 21.6% Since SmarTrend Uptrend Call (OSIR)
Comtex SmarTrend(R) - Fri Jan 09, 9:55AM CST
SmarTrend identified an Uptrend for Osiris Therapeutics (NASDAQ:OSIR) on October 28th, 2014 at $13.68. In approximately 2 months, Osiris Therapeutics has returned 21.64% as of today's recent price of $16.64.
OSIR: 15.95 (+0.28)
Update: Osiris' Deal With Stryker Positive For Investors
Andy Batts - at Seeking Alpha - Sat Jan 03, 4:41AM CST
OSIR: 15.95 (+0.28), SYK: 94.51 (+1.14)
Osiris Therapeutics (OSIR) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 7:48AM CST
Osiris Therapeutics (OSIR) Shares March Higher, Can It Continue?
OSIR: 15.95 (+0.28)
Osiris inks deal with Stryker to commercialize bone matrix
Seeking Alpha - at Seeking Alpha - Wed Dec 24, 12:19PM CST
OSIR: 15.95 (+0.28), SYK: 94.51 (+1.14)
Cell Therapy 2015: With Maturity Comes Promise
Life Sciences Report - Seeking Alpha - Wed Dec 24, 6:41AM CST
A number of new and innovative medical paradigms are being explored by companies in the life sciences sector, with one of the front-runners being cell therapy - a disruptive technology that has, in the past few years, progressed out of preclinical...
KOOL: 0.88 (-0.14), AGEN: 5.03 (-0.01), INO: 6.80 (-0.15), NBS: 3.78 (+0.14), OSIR: 15.95 (+0.28), TEVA: 56.77 (-0.58), ATHX: 2.12 (unch)
Stryker & Osiris Team Up to Market Viable Bone Matrix - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 2:50PM CST
Under the partnership, Stryker Corporation (SYK) will attain exclusive, worldwide rights to Osiris' viable bone matrix under the name BIO4.
ANIP: 62.69 (-0.43), OSIR: 15.95 (+0.28), AFFX: 11.45 (+0.02), SYK: 94.51 (+1.14)
Osiris Announces a Strategic Partnership with Stryker for Marketing Osiris' Viable Bone Matrix
Business Wire - Mon Dec 22, 3:30PM CST
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that it has entered into an exclusive, worldwide partnership with Stryker Corporation (NYSE:SYK) for the commercialization and development of Osiris' viable bone matrix tissue form. Stryker is a global leader in medical technology whose products and services are available in over 100 countries around the world. This partnership strategically aligns one of Osiris' leading regenerative medicine technologies with Stryker's innovative medical device portfolio; the resulting synergies will maximize the market potential.
OSIR: 15.95 (+0.28), SYK: 94.51 (+1.14)
Global Regenerative Medicine Market: 20.16% CAGR to 2019 Forecasts a New Research Report at ReportsnReports.com
PRWeb - Wed Dec 17, 10:30PM CST
The rise in prevalence of degenerative diseases is one of the main factors which is driving the growth of the global regenerative medicine market. Regenerative medicine is involved in the process of replacing or regenerating human tissues, cells and/or organs for normal functioning of the body. Small molecules and biologics, gene therapy, and cell therapy are the three main technologies which are used in regenerative medicine. The global market is expected to grow at a compound annual growth rate of 20.16% during the period from 2014 to 2019. Increase in demand for regenerative products and an increase in research and development are also fueling the growth in the global regenerative medicine market.
RTIX: 5.54 (+0.19), MDT: 75.26 (+0.33), PSTI: 2.91 (+0.01), OSIR: 15.95 (+0.28), OPXA: 0.71 (-0.03), FCSC: 4.75 (+0.50), BAX: 70.39 (+0.31), CYTX: 0.47 (unch)
Commit To Buy Osiris Therapeutics At $11, Earn 9.9% Annualized Using Options
at The Street - Mon Dec 15, 11:18AM CST
Investors considering a purchase of Osiris Therapeutics Inc shares, but cautious about paying the going market price of $12.83/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
OSIR: 15.95 (+0.28)
Is Osiris Therapeutics (OSIR) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 7:34AM CST
Osiris Therapeutics is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
OSIR: 15.95 (+0.28)
New medical chief at Osiris
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 8:13AM CST
OSIR: 15.95 (+0.28)
Osiris Therapeutics Announces Expansion of the Leadership Team
Business Wire - Wed Dec 03, 7:02AM CST
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, is pleased to announce the expansion of the management team with the appointment of Adrian Mollo as General Counsel and Dr. Jon Hopper as Chief Medical Officer, both reporting to Lode Debrabandere, Ph.D., President and Chief Executive Officer. Gregory Law also recently joined the Osiris management team as Vice President of Finance and Principal Accounting Officer, reporting to Philip Jacoby, Chief Financial Officer.
OSIR: 15.95 (+0.28)
Osiris Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
Business Wire - Mon Dec 01, 7:01AM CST
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that Lode Debrabandere, Ph.D., President and Chief Executive Officer, is scheduled to present at the 26th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 at 3:00 p.m. ET in New York City.
OSIR: 15.95 (+0.28)
Osiris Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results Conference Call
Business Wire - Wed Feb 11, 7:02AM CST
Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will report its financial results for fourth quarter and full year ended December 31, 2014, on Thursday, March 5, 2015. Lode Debrabandere, Ph.D., President and Chief Executive Officer, and Philip R. Jacoby, Jr., Chief Financial Officer, will provide a company update and discuss results via a webcast and conference call on Thursday, March 5, 2015, at 9:00 a.m. ET.
OSIR: 15.95 (+0.28)
Osiris Therapeutics Shares Up 18.6% Since SmarTrend's Buy Recommendation (OSIR)
Comtex SmarTrend(R) - Mon Feb 02, 9:24AM CST
SmarTrend identified an Uptrend for Osiris Therapeutics (NASDAQ:OSIR) on October 28th, 2014 at $13.68. In approximately 3 months, Osiris Therapeutics has returned 18.64% as of today's recent price of $16.23.
OSIR: 15.95 (+0.28)
Uptrend Call Working As Osiris Therapeutics Stock Rises 23.9% (OSIR)
Comtex SmarTrend(R) - Fri Jan 23, 4:47PM CST
SmarTrend identified an Uptrend for Osiris Therapeutics (NASDAQ:OSIR) on October 28th, 2014 at $13.68. In approximately 3 months, Osiris Therapeutics has returned 23.90% as of today's recent price of $16.95.
OSIR: 15.95 (+0.28)
Osiris Therapeutics Shares Up 21.2% Since SmarTrend's Buy Recommendation (OSIR)
Comtex SmarTrend(R) - Fri Jan 16, 11:12AM CST
SmarTrend identified an Uptrend for Osiris Therapeutics (NASDAQ:OSIR) on October 28th, 2014 at $13.68. In approximately 3 months, Osiris Therapeutics has returned 21.20% as of today's recent price of $16.58.
OSIR: 15.95 (+0.28)
TiGenix: A Deeply Undervalued Stem Cell Company With Upcoming Catalysts
Logribel Biostocks - Seeking Alpha - Tue Jan 13, 8:59AM CST
TiGenix ( OTC:TGXSF ) -- listed on Euronext Brussels -- is a leading but little known Belgian cell therapy biotech with an advanced adipose-derived allogeneic stem cell product platform in various clinical stages. TiGenix also has a commercialized...
PFE: 34.64 (-0.23), OSIR: 15.95 (+0.28), GSK: 47.94 (+1.99), ATHX: 2.12 (unch)
Osiris Therapeutics Up 21.6% Since SmarTrend Uptrend Call (OSIR)
Comtex SmarTrend(R) - Fri Jan 09, 9:55AM CST
SmarTrend identified an Uptrend for Osiris Therapeutics (NASDAQ:OSIR) on October 28th, 2014 at $13.68. In approximately 2 months, Osiris Therapeutics has returned 21.64% as of today's recent price of $16.64.
OSIR: 15.95 (+0.28)
Update: Osiris' Deal With Stryker Positive For Investors
Andy Batts - at Seeking Alpha - Sat Jan 03, 4:41AM CST
OSIR: 15.95 (+0.28), SYK: 94.51 (+1.14)
Osiris Therapeutics (OSIR) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 7:48AM CST
Osiris Therapeutics (OSIR) Shares March Higher, Can It Continue?
OSIR: 15.95 (+0.28)
Osiris inks deal with Stryker to commercialize bone matrix
Seeking Alpha - at Seeking Alpha - Wed Dec 24, 12:19PM CST
OSIR: 15.95 (+0.28), SYK: 94.51 (+1.14)
Cell Therapy 2015: With Maturity Comes Promise
Life Sciences Report - Seeking Alpha - Wed Dec 24, 6:41AM CST
A number of new and innovative medical paradigms are being explored by companies in the life sciences sector, with one of the front-runners being cell therapy - a disruptive technology that has, in the past few years, progressed out of preclinical...
KOOL: 0.88 (-0.14), AGEN: 5.03 (-0.01), INO: 6.80 (-0.15), NBS: 3.78 (+0.14), OSIR: 15.95 (+0.28), TEVA: 56.77 (-0.58), ATHX: 2.12 (unch)
Stryker & Osiris Team Up to Market Viable Bone Matrix - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 2:50PM CST
Under the partnership, Stryker Corporation (SYK) will attain exclusive, worldwide rights to Osiris' viable bone matrix under the name BIO4.
ANIP: 62.69 (-0.43), OSIR: 15.95 (+0.28), AFFX: 11.45 (+0.02), SYK: 94.51 (+1.14)
Osiris Announces a Strategic Partnership with Stryker for Marketing Osiris' Viable Bone Matrix
Business Wire - Mon Dec 22, 3:30PM CST
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that it has entered into an exclusive, worldwide partnership with Stryker Corporation (NYSE:SYK) for the commercialization and development of Osiris' viable bone matrix tissue form. Stryker is a global leader in medical technology whose products and services are available in over 100 countries around the world. This partnership strategically aligns one of Osiris' leading regenerative medicine technologies with Stryker's innovative medical device portfolio; the resulting synergies will maximize the market potential.
OSIR: 15.95 (+0.28), SYK: 94.51 (+1.14)
Global Regenerative Medicine Market: 20.16% CAGR to 2019 Forecasts a New Research Report at ReportsnReports.com
PRWeb - Wed Dec 17, 10:30PM CST
The rise in prevalence of degenerative diseases is one of the main factors which is driving the growth of the global regenerative medicine market. Regenerative medicine is involved in the process of replacing or regenerating human tissues, cells and/or organs for normal functioning of the body. Small molecules and biologics, gene therapy, and cell therapy are the three main technologies which are used in regenerative medicine. The global market is expected to grow at a compound annual growth rate of 20.16% during the period from 2014 to 2019. Increase in demand for regenerative products and an increase in research and development are also fueling the growth in the global regenerative medicine market.
RTIX: 5.54 (+0.19), MDT: 75.26 (+0.33), PSTI: 2.91 (+0.01), OSIR: 15.95 (+0.28), OPXA: 0.71 (-0.03), FCSC: 4.75 (+0.50), BAX: 70.39 (+0.31), CYTX: 0.47 (unch)
Commit To Buy Osiris Therapeutics At $11, Earn 9.9% Annualized Using Options
at The Street - Mon Dec 15, 11:18AM CST
Investors considering a purchase of Osiris Therapeutics Inc shares, but cautious about paying the going market price of $12.83/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
OSIR: 15.95 (+0.28)
Is Osiris Therapeutics (OSIR) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 7:34AM CST
Osiris Therapeutics is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
OSIR: 15.95 (+0.28)
New medical chief at Osiris
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 8:13AM CST
OSIR: 15.95 (+0.28)
Osiris Therapeutics Announces Expansion of the Leadership Team
Business Wire - Wed Dec 03, 7:02AM CST
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, is pleased to announce the expansion of the management team with the appointment of Adrian Mollo as General Counsel and Dr. Jon Hopper as Chief Medical Officer, both reporting to Lode Debrabandere, Ph.D., President and Chief Executive Officer. Gregory Law also recently joined the Osiris management team as Vice President of Finance and Principal Accounting Officer, reporting to Philip Jacoby, Chief Financial Officer.
OSIR: 15.95 (+0.28)
Osiris Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
Business Wire - Mon Dec 01, 7:01AM CST
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that Lode Debrabandere, Ph.D., President and Chief Executive Officer, is scheduled to present at the 26th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 at 3:00 p.m. ET in New York City.
OSIR: 15.95 (+0.28)
